Clinical Data (NASDAQ:[[ticker:CLDA]]), the Newton, MA-based drug developer, reports today that it has closed on the sale of 2.24 million shares of common stock. The stock offering brought in $32 million, of which the company plans to clear $30 million after expenses. The company is pursuing approval of its first drug, vilazodone, for treating depression. Last month, the FDA agreed to consider the company’s application for approval of the drug. Here’s a recent feature on Clinical Data’s big plans in the lucrative market for anti-depression pills.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
